← All indications
Cardiomyopathy, Dilated
A form of CARDIAC MUSCLE disease that is characterized by ventricular dilation, VENTRICULAR DYSFUNCTION, and HEART FAILURE. Risk factors include SMOKING; ALCOHOL DRINKING; HYPERTENSION; INFECTION; PREGNANCY; and mutations in the LMNA gene encoding LAMIN TYPE A, a NUCLEAR LAMINA protein.
Drugs by status
Phase 4 trials (14)
Phase 3 trials (17)
Phase 2 trials (16)
Organizations
Organization Involved with Phase 4 Indications (32)
- AstraZeneca
- GlaxoSmithKline
- Fundación Pública Andaluza
- National Heart, Lung, and Blood Institute (NHLBI)
- Huazhong University of Science and Technology
- American Heart Association
- Dong-A University
- Duke University
- Federal University of Minas Gerais
- Guangxi Medical University
- Harbin Medical University
- Nanjing University
- Shandong Provincial Hospital
- Shanxi Medical University
- Silesian University of Medicine
- Universidad Autonoma de Madrid
- Universidad Complutense de Madrid
- University of Tehran
- University of Valencia
- Fudan University
- Zhengzhou University
- University of Colorado, Denver
- University of Utah
- Vanderbilt University
- Jiao Tong University
- Government of China
- University of Barcelona
- Clinica Universidad de Navarra
- University of Colorado
- People's Liberation Army of China
- +2 more
Organization Involved with Phase 3 Indications (23)
- Array BioPharma
- Ethicare GmbH
- Ain Shams University
- Andalusian Initiative for Advanced Therapies
- University of London
- Institut National de la Santé Et de la Recherche Médicale, France
- Osaka University
- University of Oslo
- University of Seville
- University of Toronto
- Utrecht University
- University of Vienna
- Univerzitetska Decja Klinika Belgrade
- University of Ljubljana
- Hospital Universitario Puerta del Mar
- Hospital Regional Universitario Carlos Haya
- University of Paris
- University of Brescia
- Erasmus University Rotterdam
- National Natural Science Foundation of China
- Andalusian Initiative in Advanced Therapies
- Government of Brazil
- University of Malaga
Organization Involved with Phase 2 Indications (43)
- Celladon Corporation
- Corimmun GmbH
- Cumberland Pharmaceuticals
- MyoKardia, Inc.
- Vericel Corporation
- Berlin Cures GmbH
- University of Pennsylvania
- University of Pittsburgh
- Allegiance Health
- Bambino Gesù Hospital and Research Institute
- Blood Transfusion Centre of Slovenia
- Case Western Reserve University
- Northwestern University
- Oregon Health and Science University
- Qingdao University
- Stanford University
- University of Florida
- University of Medicine and Dentistry of New Jersey
- University of Miami
- University of Rochester
- Wake Forest University
- Columbia University
- St. Louis University
- University of California, San Diego
- University of Chicago
- University of Cincinnati
- University of Copenhagen
- Icahn School of Medicine at Mount Sinai
- Department of Defense
- Universidad de los Andes
- +13 more
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (13)